相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1
Xiaowei Wu et al.
CELL DEATH AND DIFFERENTIATION (2020)
BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL
Georgia Greaves et al.
CELL DEATH AND DIFFERENTIATION (2019)
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
J. Gao et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
The regulatory protein GADD34 inhibits TRAIL-induced apoptosis via TRAF6/ERK-dependent stabilization of myeloid cell leukemia 1 in liver cancer cells
Peiying Song et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Nicotine induces cell survival and chemoresistance by stimulating Mcl-1 phosphorylation and its interaction with Bak in lung cancer
Ling Liu et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
BCL2 blockade overcomes MCL1 resistance in multiple myeloma
Ka Tat Siu et al.
LEUKEMIA (2019)
Recent advances in the development of Mcl-1 inhibitors for cancer therapy
Alexander W. Hird et al.
PHARMACOLOGY & THERAPEUTICS (2019)
MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer
Xiaowei Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Investigation of B, C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents
Ho Shin Kim et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Biopharmacological considerations for accelerating drug development of deguelin, a rotenoid with potent chemotherapeutic and chemopreventive potential
Rake Sarah Varughese et al.
CANCER (2019)
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma
Dana Prukova et al.
CLINICAL CANCER RESEARCH (2019)
Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy
Viacheslav V. Senichkin et al.
TRENDS IN CELL BIOLOGY (2019)
Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAFV600E mutation bearing metastatic melanoma cells
Evan L. Carpenter et al.
MOLECULAR CARCINOGENESIS (2019)
The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells
Shaheen Kabir et al.
ELIFE (2019)
Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates
Nicolas Girard
FUTURE ONCOLOGY (2019)
Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin
Xinfang Yu et al.
ONCOGENE (2019)
Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer
Fei Cao et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2019)
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
Ana C. Z. Gelatti et al.
LUNG CANCER (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Deguelin induces apoptosis in colorectal cancer cells by activating the p38 MAPK pathway
Liubo Chen et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Repression of Hexokinases II-Mediated Glycolysis Contributes to Piperlongumine-Induced Tumor Suppression in Non-Small Cell Lung Cancer Cells
Li Zhou et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)
Deguelin attenuates non-small cell lung cancer cell metastasis through inhibiting the CtsZ/FAK signaling pathway
Wei Li et al.
CELLULAR SIGNALLING (2018)
Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis
Seiji Arai et al.
CLINICAL CANCER RESEARCH (2018)
Atypical APC/C-dependent degradation of Mcl-1 provides an apoptotic timer during mitotic arrest
Lindsey A. Allan et al.
EMBO JOURNAL (2018)
Recombinant MDA-7/IL24 Suppresses Prostate Cancer Bone Metastasis through Downregulation of the Akt/Mcl-1 Pathway
Anjan K. Pradhan et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
Shengzhe Zhang et al.
NATURE COMMUNICATIONS (2018)
Repression of Noxa by Bmi1 contributes to deguelin-induced apoptosis in non-small cell lung cancer cells
Wei Li et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Exploiting MCL1 Dependency with Combination MEK+MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer
Varuna Nangia et al.
CANCER DISCOVERY (2018)
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Delphine Merino et al.
CANCER CELL (2018)
Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
Tatsuya Nagano et al.
CELLS (2018)
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
Kyung-A Song et al.
CLINICAL CANCER RESEARCH (2018)
Deguelin, an Aurora B Kinase Inhibitor, Exhibits Potent Anti-Tumor Effect in Human Esophageal Squamous Cell Carcinoma
Xinfang Yu et al.
EBIOMEDICINE (2017)
Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation
Puyu Shi et al.
CLINICAL CANCER RESEARCH (2017)
Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis
Xinfang Yu et al.
BMC CANCER (2017)
Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer
Mingxiang Ye et al.
CANCER RESEARCH (2017)
Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells
Jingshan Tong et al.
CANCER RESEARCH (2017)
EGFR signaling defines Mcl-1 survival dependency in neuroblastoma
Srilatha Nalluri et al.
CANCER BIOLOGY & THERAPY (2015)
3,6,2′,4′,5′-Pentahydroxyflavone, an Orally Bioavailable Multiple Protein Kinase Inhibitor, Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer
Yuqiao Sheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Mcl-1 Mediates TWEAK/Fn14-Induced Non-Small Cell Lung Cancer Survival and Therapeutic Response
Timothy G. Whitsett et al.
MOLECULAR CANCER RESEARCH (2014)
HTLV-1 Tax Stabilizes MCL-1 via TRAF6-Dependent K63-Linked Polyubiquitination to Promote Cell Survival and Transformation
Young Bong Choi et al.
PLOS PATHOGENS (2014)
Mcl-1 Ubiquitination: Unique Regulation of an Essential Survival Protein
Barbara Mojsa et al.
CELLS (2014)
Trim17-mediated ubiquitination and degradation of Mcl-1 initiate apoptosis in neurons
M. M. Magiera et al.
CELL DEATH AND DIFFERENTIATION (2013)
Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis
Hanshi Sun et al.
BLOOD (2011)
SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction
Hiroyuki Inuzuka et al.
NATURE (2011)
Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer
E. P. Booy et al.
ONCOGENE (2011)
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
David Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William Pao et al.
NATURE REVIEWS CANCER (2010)
Degradation of Mcl-1 by β-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization
Qingqing Ding et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1
U Maurer et al.
MOLECULAR CELL (2006)
Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis
Q Zhong et al.
CELL (2005)
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions
W Pao et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
分享论文
